Bristol Myers Squibb Co (BMY): Joseph C Caldarella , SVP & Controller of Bristol Myers Squibb Co sold 3,519 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were sold at $72.46 per share for a total value of $255,004.33 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Sandra Leung (EVP, General Counsel) sold 72,544 shares at $70.39 per share price.On May 6, 2016, Lamberto Andreotti (director) sold 23,200 shares at $70.54 per share price.Also, On May 5, 2016, Giovanni Caforio (Chief Executive Officer) sold 34,594 shares at $71.31 per share price.On May 4, 2016, Autenried Paul Von (SVP, Enterp. Services & CIO) sold 37,258 shares at $71.93 per share price.
Bristol-Myers Squibb Co: On Monday, May 16, 2016 heightened volatility was witnessed in Bristol-Myers Squibb Co which led to swings in the share price. The shares opened for trading at $71.42 and hit $73.01 on the upside , eventually ending the session at $72.83, with a gain of 2.32% or 1.65 points. The heightened volatility saw the trading volume jump to 50,30,729 shares. The 52-week high of the share price is $73.06 and the company has a market cap of $121,576 M . The 52-week low of the share price is at $51.82.
Company has been under the radar of several Street Analysts.Bristol-Myers Squibb Co is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $73 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $70 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Initiated by Societe Generale to Sell and the brokerage firm has set the Price Target at $48. The Rating was issued on Apr 6, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.